Addiction medication Vigabatrin proves successful in pet weight loss study Vigabatrin.

Vigabatrin is undergoing U currently.S. Food and Drug Administration -approved Stage II scientific trials against cocaine and methamphetamine addiction across the U.S. In today’s study, pets genetically bred to end up being obese experienced a loss of up to 19 % of their total pounds while nonobese animals lost 12 to 20 % following short-term vigabatrin administration. Our results may actually demonstrate that vigabatrin induced satiety in these animals, said Amy DeMarco, who led the study, employed in the laboratory of Brookhaven Lab senior scientist Stephen Dewey.This article is republished with kind authorization from our friends at The Kaiser Family Foundation. You will see the complete Kaiser Daily Health Policy Survey, search the archives, or sign up for email delivery of in-depth coverage of wellness policy developments, discussions and debates. The Kaiser Daily Health Policy Report is published for, a free of charge provider of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Panel Kaiser and Company Family members Foundation. All rights reserved.

ADVANTAGE, ITA to put into action proprietary oncology decision-support platform To improve manage and outcomes costs for members with cancer, ADVANTAGE Health Solutions, Inc.SM has contracted with ITA Partners to implement eviti – ITA’s proprietary oncology decision-support platform – across their supplier network.